Barriers to immune cell infiltration in tumors
Journal for ImmunoTherapy of Cancer · 2023-04 · 11 (4) · e006401
DOI: 10.1136/jitc-2022-006401 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.04.2023. Verfasst von Marit M Melssen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 171-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Cancer Research Institute.
Abstract (Originalsprache)
Increased immune cell infiltration into tumors is associated with improved patient survival and predicts response to immune therapies. Thus, identification of factors that determine the extent of immune infiltration is crucial, so that methods to intervene on these targets can be developed. T cells enter tumor tissues through the vasculature, and under control of interactions between homing receptors on the T cells and homing receptor ligands (HRLs) expressed by tumor vascular endothelium and tumor cell nests. HRLs are often deficient in tumors, and there also may be active barriers to infiltration. These remain understudied but may be crucial for enhancing immune-mediated cancer control. Multiple intratumoral and systemic therapeutic approaches show promise to enhance T cell infiltration, including both approved therapies and experimental therapies. This review highlights the intracellular and extracellular determinants of immune cell infiltration into tumors, barriers to infiltration, and approaches for intervention to enhance infiltration and response to immune therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden.
- Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia, USA.
- Surgery, University of Iowa, Iowa City, Iowa, USA.
- Surgery, University of Virginia, Charlottesville, Virginia, USA cls8h@virginia.edu.
ORCID-Profile: Marit M Melssen, Craig L Slingluff
Förderung
- NIH HHS
- NCI NIH HHS
- Cancer Research Institute
- NCI F99/K00 Predoctoral to Postdoctoral Transition Award
- Rebecca Clary Harris Fellowship
- Barncancerfonden
- NIH Director's Early Independence Award DP5
- U.S. Public Health Service
Zitieren
APA
Melssen, M. M., Sheybani, N. D., Leick, K. M., & Slingluff, C. L. (2023). Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer, 11(4), e006401. https://doi.org/10.1136/jitc-2022-006401
Vancouver
Melssen MM, Sheybani ND, Leick KM, Slingluff CL. Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer. 2023;11(4):e006401. doi:10.1136/jitc-2022-006401
BibTeX
@article{Melssen2023,
author = {Melssen, Marit M and Sheybani, Natasha D and Leick, Katie M and Slingluff, Craig L},
title = {Barriers to immune cell infiltration in tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {4},
pages = {e006401},
doi = {10.1136/jitc-2022-006401}
}
EUVIMED